543 related articles for article (PubMed ID: 27370570)
21. Cancer prevention and therapy through the modulation of transcription factors by bioactive natural compounds.
Shanmugam MK; Lee JH; Chai EZ; Kanchi MM; Kar S; Arfuso F; Dharmarajan A; Kumar AP; Ramar PS; Looi CY; Mustafa MR; Tergaonkar V; Bishayee A; Ahn KS; Sethi G
Semin Cancer Biol; 2016 Oct; 40-41():35-47. PubMed ID: 27038646
[TBL] [Abstract][Full Text] [Related]
22. Targeting the signalling pathways regulated by deubiquitinases for prostate cancer therapeutics.
Islam MT; Zhou X; Chen F; Khan MA; Fu J; Chen H
Cell Biochem Funct; 2019 Jul; 37(5):304-319. PubMed ID: 31062387
[TBL] [Abstract][Full Text] [Related]
23. Diterpenes from Cryptomeria japonica inhibit androgen receptor transcriptional activity in prostate cancer cells.
Tu WC; Wang SY; Chien SC; Lin FM; Chen LR; Chiu CY; Hsiao PW
Planta Med; 2007 Oct; 73(13):1407-9. PubMed ID: 17924310
[TBL] [Abstract][Full Text] [Related]
24. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.
Colditz J; Rupf B; Maiwald C; Baniahmad A
Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825
[TBL] [Abstract][Full Text] [Related]
25. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
[TBL] [Abstract][Full Text] [Related]
26. Potential of neem (Azadirachta indica L.) for prevention and treatment of oncologic diseases.
Patel SM; Nagulapalli Venkata KC; Bhattacharyya P; Sethi G; Bishayee A
Semin Cancer Biol; 2016 Oct; 40-41():100-115. PubMed ID: 27019417
[TBL] [Abstract][Full Text] [Related]
27. Endocrine prevention and treatment of prostate cancer.
Tammela TL
Mol Cell Endocrinol; 2012 Sep; 360(1-2):59-67. PubMed ID: 22465099
[TBL] [Abstract][Full Text] [Related]
28. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM
Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127
[TBL] [Abstract][Full Text] [Related]
29. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
30. Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.
Raina K; Kumar D; Agarwal R
Semin Cancer Biol; 2016 Oct; 40-41():116-129. PubMed ID: 27452666
[TBL] [Abstract][Full Text] [Related]
31. Bioactive natural products against prostate cancer: mechanism of action and autophagic/apoptotic molecular pathways.
Gioti K; Tenta R
Planta Med; 2015 May; 81(7):543-62. PubMed ID: 25875508
[TBL] [Abstract][Full Text] [Related]
32. The hallmarks of castration-resistant prostate cancers.
Katsogiannou M; Ziouziou H; Karaki S; Andrieu C; Henry de Villeneuve M; Rocchi P
Cancer Treat Rev; 2015 Jul; 41(7):588-97. PubMed ID: 25981454
[TBL] [Abstract][Full Text] [Related]
33. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
34. Leading causes of castration-resistant prostate cancer.
Lu M; Lu H; Kong Q
Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
[TBL] [Abstract][Full Text] [Related]
35. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
[TBL] [Abstract][Full Text] [Related]
37. Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer.
McCarty MF; Hejazi J; Rastmanesh R
Integr Cancer Ther; 2014 Sep; 13(5):386-95. PubMed ID: 24867960
[TBL] [Abstract][Full Text] [Related]
38. Achieving resistance specificity in prostate cancer.
Wadhwa B; Dumbre R
Chem Biol Interact; 2016 Dec; 260():243-247. PubMed ID: 27720870
[TBL] [Abstract][Full Text] [Related]
39. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
40. The strategies to control prostate cancer by chemoprevention approaches.
Ting H; Deep G; Agarwal C; Agarwal R
Mutat Res; 2014 Feb; 760():1-15. PubMed ID: 24389535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
